Ocrelizumab for psychosis linked to an overactive immune system
Treatments studied
Part of Mental health clinical trials.
This Phase 1/2 study tests ocrelizumab, a medicine that affects parts of the immune system, to see if it can improve psychosis symptoms in people with schizophrenia-spectrum disorders. It’s mainly for younger adults with ongoing psychosis and evidence that the symptoms began early in life, with certain infection/vaccine safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 35 years old (any sex).
- You have an ongoing psychotic disorder for at least 6 months that fits schizophrenia-spectrum criteria.
- Your symptom scores are high enough (a total PANSS of 60 or more, and positive symptoms score 4+ on at least two areas).
- Your school performance was normal at least until age 15, and you did not have psychiatric symptoms before age 15.
- If you take antipsychotic medicine, your dose hasn’t changed within the last 2 weeks before the main symptom check.
- You must be able to agree to the study (consent) or, if needed, assent, and complete study testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests rituximab (an immune system medicine) to see if it can reduce OCD symptoms and/or psychosis when there are signs the immune system may be involved. You may be considered if other standard psychiatric treatments have not helped enough and your illness seems relatively recent with possible inflammation clues.
This study tests whether a new medication that targets immune system inflammation (IL-23) can help people with schizophrenia feel better. Researchers believe this immune approach might reduce symptoms when combined with regular antipsychotic treatment.
This study looks at how immune system health relates to brain changes in people with schizophrenia. It uses brain imaging and electrical activity tests to understand these connections.
This trial tests if ocrelizumab, given as a shot under the skin, is safe and works for children and teens with relapsing-remitting multiple sclerosis (RRMS). It aims to help control relapses and slow the disease.
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.